Substituted heteroaromatic compounds: Effect on nicotine self-administration in rats

Psychopharmacology

Volumn 221, Issue 4, 2012, Pages 637-648

  Cashman, John R ^a   Okolotowicz, Karl ^a   Cerny, Matt ^a   Johnson, Robert ^b   Janowsky, Aaron ^b   Azar, Marc R ^c  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Behavioral Pharma Inc   (United States)

Author keywords

Cytochrome P 450 2A6; Dopamine transporter; Neuronal nicotinic acetylcholine receptors; Nicotine metabolism; Nicotine self administration

Indexed keywords

AROMATIC COMPOUND; COTININE; CYTOCHROME P450 2A6; DOPAMINE TRANSPORTER; HETEROAROMATIC COMPOUND; NICOTINE; NICOTINIC RECEPTOR ALPHA4; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; EXPERIMENTAL RAT; IC 50; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TOBACCO DEPENDENCE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MALE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, WISTAR; SELF ADMINISTRATION;

EID: 84862691418     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2608-6     Document Type: Article

References (37)

1. Baggaley KH, Heald M, Hindley RM, Morgan B, Tee JL, Green J (1975) Hypolipidemic imidazoles. J Med Chem 18:833-836
2. Balfour DJ (2002) The neurobiology of tobacco dependence: a commentary. Respiration 69:7-11
3. Benowitz NL (1988) Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 319:1318-1330
4. Benowitz NL, Jacob P 3rd (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35:499-504
5. Berkman CE, Park SB, Wrighton SA, Cashman JR (1995) In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 50:565-570
6. Cahill K, Stead L, Lancaster T (2009) A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Safety 32 (2):119-135. doi:10.2165/00002018-200932020-00005
7. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P 3rd, Benowitz NL (1992) Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chem Res Toxicol 5:639-646
8. Cheng Y, Prusoff WH (1973) Relationship between the Ki value and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
9. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT (2005) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477
10. Denton TT, Zhang X, Cashman JR (2004) Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol 67:751-756
11. Denton TT, Zhang X, Cashman JR (2005) 5-Substituted, 6-substituted and unsubstituted 3-heteroaromatic pyridine analogs of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem 48:224-239
12. Doll R, Hill AB (1952) A study of the aetiology of carcinoma of the lung. Br Med J 2(4797):1271-1286
13. Eshleman AJ, Carmolli M, Cumbay M, Neve KA, Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exper Ther 289:877-885
14. Feng X, Fandrick K, Johnson R, Janowsky A, Cashman JR (2003) Synthesis of 3-carbomethoxy-4-(aryl)piperidines and in vitro and in vivo pharmacological evaluation: identification of inhibitors of the human dopamine transporter. Bioorg Med Chem 11:775-780
15. Feyerabend C, Ings RM, Russel MA (1985) Nicotine pharmacokinetics and its application to intake from smoking. Br J Clin Pharmacol 19:239-247
16. Hirayama T (1981) Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan. Br Med J (Clin Res Ed) 282:183-185
17. Hughes JR (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev 3:CD000146. doi:10.1002/14651858CD000146. pub2
18. Hyytia P, Schulteis G, Koob GF (1996) Intravenous heroin and ethanol self-administration by alcohol-preferring AA and alcohol-avoiding ANA rats. Psychopharmacol (Berl) 125:248-254
19. Jones J, Raiff BR, Dallery J (2010) Nicotine's enhancing effects on responding maintained by conditioned reinforcers are reduced by pretreatment with mecamylamine, but not hexamethonium, in rats. Exp Clin Psychophrmacol 18:350-358
20. Kruse LI, Kaiser C, DeWolf WE, Finkelstein JA, Frazee JS, Hilbert EL, Ross ST, Flaim KE, Sawyer JL (1990) Some benzylsubstituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine betahydroxylase. 4. Structure-activity relationships at the copper binding site. J Med Chem 33:781-789
21. Lu P, Alterman MA, Chaurasia CS, Bambal RB, Hanzlik RP (1997) Heme-coordinating analogs of lauric acid as inhibitors of fatty acid omega-hydroxylation. Arch Biochem Biophys 337:1-7
22. MacDougall JM, Fandrick K, Zhang X, Serafin SV, Cashman JR (2003) Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues. Chem Res Toxicol 16:988-993
23. Mathews CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 11:2011-2030
24. Miksys S, Hoffmann E, Tyndale RF (2000) Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 59:1501-1511
25. Pianezza ML, Sellers EM, Tyndale RF (1998) Nicotine metabolism defect reduces smoking. Nature 393:750
26. Rock VJ, Malarcher A, Kahende JW, Asman K, Husten C, Caraballo R (2007) Cigarette smoking among adults-United States, 2006. MMWR 56:1157-1161
27. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE (2007) Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316-325
28. Sellers EM, Kaplan HL, Tyndale RF (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68:35-43
29. Sellers EM, Tyndale RF, Fernandes LC (2003) Decreasing smoking behavior and risk through CYP2A6 inhibition. Drug Discov Today 8:487-493
30. Sharples SC, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, Spencer JA, Gallagher T, Whiteaker P, Wonnacutt S (2000) UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783-2791
31. Shin VY, Jin HC, Ng EK, Yu J, Leung WK, Cho CH, Sung JJ (2008) Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 233:254-261
32. Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 1:CD000146
33. Takeuchi H, Saoo K, Yokohira M, Ikeda M, Maeta H, Miyazaki M, Yamazaki H, Kamataki T, Imaida K (2003) Pretreatment with 8- methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone in female A/J mice. Cancer Res 66:7581-7583
34. Taylor AL, Bettcher DW (2000) WHO framework convention on tobacco control: a global "good" for public health. Bull World Health Organ 78:920-929
35. Verras A, Kuntz ID, Ortiz de Montellano PR (2004) Computer-assisted design of selective imidazole inhibitors for cytochrome P450 Enzymes. J Med Chem 47:3572-3579
36. West R (2007) The clinical significance of "small" effects of smoking cessation treatments. Addiction 102:506-509
37. Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF, Cashman JR (2006) Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition and protein co-crystallization. J Med Chem 49:6987-7001